Written by Kathy F. Mahdoubi
While 18F-FDG PET is the gold standard for evaluating and managing patients with lung cancer, recent data have shown it also could be beneficial in diagnosing, staging and monitoring of small cell lung cancer.
Siemens Healthcare has released a low-dose information center on the Internet for continuing education and information about dose reduction. Aimed at doctors and clinical personnel, the platform was designed to help keep professionals up-to-date on important factors in radiation reduction in radiology and nuclear medicine, according to Siemens.
Written by Kaitlyn Dmyterko
DENVER—Incorporating coronary artery calcium screening (CAC) into practice can change the diagnoses and management of coronary artery disease (CAD), however, it may still be too early to tell how it will impact patient outcomes, Tim M. Bateman, MD, co-director of cardiovascular radiologic imaging at Mid America Heart Institute, Saint Luke's Health System in Kansas City, said during a presentation Sept. 11 at the 16th annual American Society of Nuclear Cardiology (ASNC) scientific session.
Written by Kaitlyn Dmyterko
DENVER—Coronary CT Angiography (CCTA) is not indicated for use in atrial fibrillation (AF) patents due to the problems it causes in terms of diagnostic accuracy, Thomas C. Gerber, MD, PhD, of the division of cardiovascular diseases at the Mayo Clinic, Jacksonville, Fla., said during a presentation Sept. 10 at the annual scientific sessions of the American Society of Nuclear Cardiology (ASNC). However, cardiac CT may be beneficial in some instances for this patient population when the right methods are used.
Written by Kaitlyn Dmyterko
DENVER—When performing nuclear imaging studies, it is important to balance benefits against potential risks, however, it is most imperative to ensure that only appropriate patients are being imaged, George A. Beller, MD, a cardiologist at the University of Virginia Health System in Charlottesville, said during a presentation Sept. 10 at the 16th annual American Society of Nuclear Cardiology (ASNC) scientific session.
DENVER—As important players within the medical community work to reduce unnecessary radiation exposure from medical imaging, integrating protocols and strategies, such as shielding, can help reduce dose, James A. Case, PhD, of Cardiovascular Imaging Technologies in Kansas City, said during a presentation Sept. 9 at the 16th annual American Society of Nuclear Cardiology (ASNC) meeting.
A patient-specific, 3D dosimetry protocol using the radiopharmaceutical Tc-HYNIC-TOC is clinically feasible to demonstrate large dose variations in neuroendocrine tumors and normal organs, according to study findings published Sept. 1 in the Journal of Nuclear Medicine.
The American College of Radiology (ACR) is seeking to clarify the Joint Commission's Sentinel Event Alert, related to radiation-based imaging.
Written by James Brice
Slowly but steadily, radiation oncologists are adopting PET and PET/CT to measure the early response of cancers to radiotherapy and other treatments. And progress has been significant.
Written by Leslee J. Shaw, PhD, FASNC
The 16th annual scientific session of the American Society of Nuclear Cardiology (ASNC), Sept. 8-11, brings together scientists, clinicians and industry to establish and discuss optimal standards of imaging care.
Researchers found the newly-developed radiopharmaceutical C-4DST safe and effective for imaging brain tumors in a pilot study published Aug. 1 in the Journal of Nuclear Medicine.
Written by Lisa Fratt
Microscopic gold particles could multiply the effectiveness of standard cancer radiation therapy by acting as tiny missiles that destroy blood vessels feeding cancerous tumors. Early research about this method, which could shorten cancer treatment and make it more effective, is being presented at the 2011 Joint Meeting of the American Association of Physicists in Medicine (AAPM) and Canadian Organization of Medical Physicists (COMP).
Two tiny genetic variations can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment, according to a genome-wide association study (GWAS) published online July 24 in Nature Medicine. Knowing in advance who is at risk could help physicians tailor treatment to reduce the risks for patients who are most susceptible to long-term damage.
Researchers found low fetal radiation exposures in a retrospective study assessing the effects of F-FDG PET studies performed on pregnant patients with cancer, according to findings published in the July issue of the Journal of Nuclear Medicine.
The National Institutes of Health (NIH) have awarded researchers from Rensselaer Polytechnic Institute in Troy, N.Y., a $1.2 million grant to develop software and patient-specific virtual phantoms to calculate and track patient radiation exposure from CT imaging.
Fleming Pharmaceuticals has ramped up production of ThyroShield, a liquid potassium iodide product indicated for thyroid protection in radiation emergencies, to meet increased domestic and international demand.
Novelos Therapeutics has completed its acquisition of Cellectar and $5.1 million financing to develop three novel cancer-targeted compounds.
New recommendations from the American Thyroid Association on outpatient radioiodine (131I) treatment to minimize unintended radiation exposure and maximize the safety of patients, their families and the public have been published in the April issue of Thyroid.
NEW ORLEANS—With the risks of radiogenic cancer sparking concerns among patients and cardiologists, Andrew Einstein, MD, PhD, of Columbia University Medical Center in New York City, suggested that stakeholders consider radiation risks in balance with the benefits of the proposed imaging study. Einstein and a panel of presenters shared a list of strategies for reducing radiation dose across the spectrum of cardiovascular imaging modalities during a presentation at the annual meeting of the American College of Cardiology.
Outpatient intra-arterial yttrium-90 (Y-90) radioembolization provides an anti-tumoral effect in liver cancer patients where chemotherapy failed, according to a multi-institutional study presented at the Society of Interventional Radiology's 36th annual scientific meeting in Chicago. The study examined the impact of treating liver tumors with higher doses of Y-90 than previously tried.
|
RSS 
